



**Date:** July 1, 2021

**Re:** New Prescription Drug Notice from Novo Nordisk Inc. – Wegovy™

**Submitted via e-mail:** [AGO.highcostprescriptiondrugs@vermont.com](mailto:AGO.highcostprescriptiondrugs@vermont.com)

To the Vermont Attorney General Office

On June 16, 2021, Novo Nordisk Inc. submitted notice of a new prescription drug to market from Novo Nordisk Inc. for Wegovy™.

Pursuant to 18 V.S.A. § 4637 (C), Novo Nordisk Inc. is providing the additional Information:

<b>NDC</b>	00169-4525-14	00169-4505-14	00169-4501-14	00169-4517-14	00169-4524-14
<b>Drug Product Description</b>	0.25 mg/0.5 mL in 1 pre-filled pen; 4 pens in 1 carton	0.5 mg/0.5 mL in 1 pre-filled pen; 4 pens in 1 carton	1 mg/ 0.5 mL in 1 pre-filled pen; 4 pens in 1 carton	1.7 mg/0.75 mL in 1 pre-filled pen; 4 pens in 1 carton	2.4 mg/0.75 mL in 1 pre-filled pen; 4 pens in 1 carton
<b>Introduced to Market Date</b>	6/16/2021	6/16/2021	6/16/2021	6/16/2021	6/16/2021
<b>WAC at Introduction</b>	\$ 1,349.02	\$ 1,349.02	\$ 1,349.02	\$ 1,349.02	\$ 1,349.02
<b>Marketing &amp; Pricing Plan</b>	Marketing and Pricing Plans are not publicly available information				
<b>Estimated Volume of Patients</b>	2,600,000 Regarding the reported patient estimate, per IQVIA's Longitudinal Access and Adjudication Database, citing 2020 year data, there are currently 2.6 million patients on pharmacotherapy medication for anti-obesity in the US. For the estimated patients requirement, Novo Nordisk utilizes this number of estimated patients on pharmacotherapy, however, we note that the total number of patients diagnosed with obesity is roughly 30 million, the majority of those patients will not go onto an anti-obesity pharmacotherapy treatment. Please note, this is not an estimate of prescriptions that might be written for Wegovy™ or each available dose of Wegovy™. Wegovy™ will represent a portion of the broader market for anti-obesity therapies.				
<b>Breakthrough therapy?</b>	No	No	No	No	No
<b>Priority Review?</b>	Yes	Yes	Yes	Yes	Yes
<b>Acquisition Date</b>	N/A	N/A	N/A	N/A	N/A
<b>Acquisition Price</b>	N/A	N/A	N/A	N/A	N/A

Amie Phillips Pablo

Director, Ethics & Compliance